Cipla shares in focus after Goa facility receives form 483 with one observation from USFDA

Cipla shares will remain in focus on Tuesday, 21 January, after the company announced that the United States Food and Drug Administration (USFDA) conducted an inspection of its wholly-owned subsidiary, Medispray Laboratories Pvt Ltd, in Kundaim, Goa, from 14-20 January 2025, resulting in one observation noted in Form 483.

In a regulatory filing, Cipla stated, "The United States Food and Drug Administration (USFDA) conducted an inspection at the manufacturing facility of Medispray Laboratories Private Limited, a wholly owned subsidiary of the Company, located in Kundaim, Goa, from 14th – 20th January, 2025."

Following the inspection, the facility received one observation in Form 483. Cipla assured that it would work closely with the USFDA to address the observation comprehensively within the required timeline.


"At the conclusion of the inspection, Medispray received one observation in Form 483. The company will collaborate with the USFDA and is committed to addressing the observation within the stipulated time frame," Cipla added.

Also Read: RBI injects Rs 76,000 crore more to boost liquidity, rein in call money rates

What is Form 483?

Form 483 is issued by the USFDA to manufacturers when an inspection reveals conditions that may violate regulatory requirements. It outlines any observed deficiencies related to Good Manufacturing Practices (GMP) and other regulatory standards. While receiving a Form 483 does not automatically imply that enforcement actions will be taken, the company must address the observations and provide a response to the FDA, outlining corrective actions to remedy the issues. Failure to adequately address the observations may lead to further regulatory action, including warning letters or import bans.

Also Read: Budget 2025: Can KAVACH be a game-changer for Siemens, Quadrant Future, and 4 more stocks?

Cipla shares target price

As per Trendlyne data, the average target price of the stock is Rs 1,641, which indicates an upside of 14% from the current market prices. The consensus recommendation from 37 analysts for the stock is a 'Buy'.

Cipla shares performance

Cipla shares have surged 10% over the past 12 months and 64% over the last three years. The company’s market capitalization currently stands at Rs 1,16,772 crore.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)